- Home
- SSNC vs BIIB Comparison
SSNC vs BIIB Comparison
Compare SSNC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSNC
- BIIB
- Stock Information
- Founded
- SSNC 1986
- BIIB 1978
- Country
- SSNC United States
- BIIB United States
- Employees
- SSNC N/A
- BIIB N/A
- Industry
- SSNC EDP Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- SSNC Technology
- BIIB Health Care
- Exchange
- SSNC Nasdaq
- BIIB Nasdaq
- Market Cap
- SSNC 20.3B
- BIIB 19.9B
- IPO Year
- SSNC 1996
- BIIB 1991
- Fundamental
- Price
- SSNC $83.53
- BIIB $136.84
- Analyst Decision
- SSNC Strong Buy
- BIIB Buy
- Analyst Count
- SSNC 6
- BIIB 27
- Target Price
- SSNC $99.50
- BIIB $220.50
- AVG Volume (30 Days)
- SSNC 1.4M
- BIIB 1.7M
- Earning Date
- SSNC 04-24-2025
- BIIB 04-23-2025
- Dividend Yield
- SSNC 1.20%
- BIIB N/A
- EPS Growth
- SSNC 25.52
- BIIB 40.28
- EPS
- SSNC 3.00
- BIIB 11.18
- Revenue
- SSNC $5,882,000,000.00
- BIIB $9,675,900,000.00
- Revenue This Year
- SSNC $7.38
- BIIB N/A
- Revenue Next Year
- SSNC $5.05
- BIIB N/A
- P/E Ratio
- SSNC $27.70
- BIIB $12.25
- Revenue Growth
- SSNC 6.89
- BIIB N/A
- 52 Week Low
- SSNC $59.63
- BIIB $128.51
- 52 Week High
- SSNC $89.73
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- SSNC 50.06
- BIIB 40.35
- Support Level
- SSNC $82.25
- BIIB $138.65
- Resistance Level
- SSNC $84.46
- BIIB $144.07
- Average True Range (ATR)
- SSNC 1.60
- BIIB 3.37
- MACD
- SSNC 0.04
- BIIB -0.48
- Stochastic Oscillator
- SSNC 80.86
- BIIB 18.92
About SSNC SS&C Technologies Holdings Inc.
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in virtual deal room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.